Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Cinclus Pharma, Audiocast, Q3'26

By Inderes11/11/2026, 1:00 PM
Cinclus Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christer Ahlberg
00:00 - 09:41

Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We will walk you through the key developments from the third quarter, after which we will be happy to answer any questions you may have. Our lead asset, linaprazan glurate, is the next-generation PCAB that offers sustained around-the-clock acid control that distinguishes it from the rest. From both PPIs and all other PCABs in severe erosive GERD. The patient population we are addressing is large and underserved. Roughly 10 million people across the US and Europe live with severe erosive GERD, and globally, 19 million, with a substantial share of them not adequately healed by today's standard of care. This makes this a specialist-driven commercial opportunity rather than a primary care one. Superior acid control translates directly into better healing, faster healing, and better symptom control, which will give us a clinically and commercially differentiated product. Our Phase III program began in September 2025, and I am pleased to report that HEEALING1 is now complete with 523 patients randomized, exceeding the protocol-specified target of 501 patients, and all planned patient visits were completed in September. As we have communicated earlier, HEEALING1 topline results are expected this quarter, which of course could be a major value inflection point for Cinclus Pharma. The program continues to be well de-risked at this stage; we have a robust clinical data package and alignment from both FDA and EMA on our regulatory strategy. And we also have a well-defined CMC plan. We see that the first-generation PCABs are rapidly gaining traction. PCABs are now available in more than 30 countries, and local treatment guidelines are incorporating PCABs into the treatment recommendations. It's clear that PCABs are about to take over the market from the current standard of care treatment with PPIs. Linaprazan glurate has been launched in China in 2026 by Huadong, the commercialization partner of our license partner, Sinorda. The launch has achieved broad coverage across Chinese markets with a significant increase in sales volume compared with the previous quarter. The third quarter marked the completion of several important milestones for HEEALING1, and in July, we reached the study randomization target. In September, the final patient completed the eight-week treatment period, followed later that month by the final safety follow-up visit, completing all planned patient visits in the study after the end of the quarter. Results from the Phase I studies of Linaprazan glurate were published in Alimentary Pharmacology and Therapeutics. The studies demonstrated rapid and sustained acid control with close to 100% pH control at the highest dose levels. Okay, let's go into the HEEALING1 study. Let me provide an update on the HEEALING1 study as we approach the topline readout. Exciting times. So, a total of 523 patients from eight European countries were randomized into HEEALING1, exceeding our protocol-specified target of 501 patients. All planned patient visits in the study have been completed. The study has progressed on schedule with rapid patient recruitment, which highlights the substantial unmet medical need and demand for more effective treatment of erosive GERD. The primary endpoint is superiority to lansoprazole in healing of severe erosive GERD. Of the patients with grade C and D, the severe patients, this should be done after four weeks of treatment. Key secondary endpoints cover healing and symptom relief through four and eight weeks for both the severe patients and the full intent-to-treat population, but also for all patients including grades A, B, C, and D. HEEALING2. Our second and final Phase III study will evaluate patients suffering from erosive GERD with acute and maintenance therapy at clinical sites in Europe, the EU, and the US. It is planned to initiate following HEEALING1 topline results during June 2027. We are anticipating topline results from the HEEALING1 study this quarter, as we have previously stated, with a good margin before the holiday season in late December. Okay, let's look into the 24-hour acid control. You have seen this chart before, but it is a very important one. The relation between acid control and healing is well established. It is a biomarker. The greater the percentage of time that gastric pH is maintained above four, the higher the healing rate. This is particularly important in severe erosive GERD, where prolonged exposure to gastric acid damages the lining of the esophagus, and effective acid suppression is critical to enable healing. This slide illustrates the number of hours that pH in the stomach is below four, with different treatment alternatives. If we start from the left with the old H2 blockers such as Zantac that were launched during the 70s, pH was below four during approximately 16 hours. Still, they became the most sold drugs in the world and were very successful. The pH below four was reduced to seven to 14 hours. With the introduction of PPIs, which you also know about, they became a huge commercial success. And then we have the first-generation PCAB launches, such as vonoprazan and tegoprazan. They have reduced the time below pH 4. The time below pH 4 is reduced to 4 to 7 hours. Our studies show that Linaprazan glurate pH is below four for only one hour per day. A major improvement to all existing treatment alternatives, highlighting a best-in-class profile with significant market potential. A sustained acid control profile is particularly relevant for patients with severe erosive GERD, where achieving sufficient acid suppression remains an important unmet need. This slide brings together the pharmacologic and clinical profile we have discussed. In the table to the left, you can see that linaprazan glurate has the highest level of 24-hour acid control reported for any other drug in both PPI and PCAB classes. You can also see that Linaprazan glurate has a quicker time to reach a pH above four and the full effect after the first dose, which is in contrast to what you see with PPIs and Vonoprazan. Also seen to the right. Thanks to these advantages. No disadvantages are apparent. To the left. The ambition is now to show that linaprazan glurate offers, in comparison to PPIs, better healing, faster healing, half the time to full healing, and better symptom relief compared to what you have seen with other PCABs. So that is, in a nutshell, what we mean when we describe linaprazan glurate as a next-generation PCAB with a best-in-class profile. So let's turn to Magnus to review our financial results for the quarter. Please go ahead, Magnus.

Magnus Christensen
09:42 - 12:47

Thank you. Christer. Yeah. You can move to slide 11. We can see the Q3 financial highlights and the third-quarter results. In Q3, we had a cash balance of 288.1 million, and this reflects continued focus and investment in the HEEALING1 study. And now, all planned patient visits have been completed in Q3. As Christer mentioned, R&D expenses remained a clear driver. Our cost base was 94% of operating expenses in Q3, compared with an average of 88% over the prior four quarters. This is consistent with our expectations for the quarter and relates primarily to all patients having now completed the planned visits in the quarter. And if you move to slide number 12, we can look at the year-over-year comparison. Net sales were almost 2 million SEK. And the revenue consisted primarily of the licensing income from the Zentiva partnership for the commercialization of Linaprazan glurate in Europe, and also royalties from Sinorda in China. Revenue from the Zentiva deal, which included an upfront payment of €13 million in quarter two 2025, is being amortized across the phase three studies on the financial net line. We recorded -4.4 million, reflecting interest income and cash, interest payments, currency revaluation, and revaluation of the structured financing. Net loss for the quarter was 114 million, primarily driven by the higher R&D expenses from the ongoing Phase III study. And if you look at the balance sheet, we have the non-current assets decreased by a little bit more than 3 million Swedish kronor, primarily reflecting the leasing liabilities for the new office premises. Other current assets decreased by 9 million, mainly due to prepayments to the CRO. In line with the contract, cash decreased by 259 million, which relates mainly to the increased R&D expenses as Phase III activity continues at full execution. If we look at non-current liabilities, they decreased by 26, which for the most part represents the contract liability from the Zentiva deal amortized by one year; current liabilities increased by 119, which is primarily driven by the structured financing in debt, convertibles, and warrants, plus the short-term contract liability from the Zentiva deal and also accruals for the HEEALING1 study. Overall, our financial position remains in line with our Phase III execution plan, and we estimate the current working capital is sufficient into the fourth quarter of 2027, according to current plans and assumptions. And with this, I conclude the financial part and hand back over to Christer.

Christer Ahlberg
12:50 - 13:51

Okay. Thank you. Thank you. That brings us to the end of the formal remarks before we open the line for questions. A few important days lie ahead. Q4 results will be reported on February 17th next year. Our 2026 annual report will be published on April 16th, and our Annual General Meeting will be held on May 20th next year. And of course, we expect to present the Phase III topline results from HEEALING1 this quarter. You will also be invited to a specific webcast on that as well. And of course, these topline results will define the clinical milestones ahead for the company. That's important, of course, for us. So with that, I would like to open the line for questions. So. Operator, please go ahead.

Operator
13:52 - 14:10

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Arvid Nicator from Carnegie. Please go ahead.

Unknown 1
14:13 - 15:02

Hi. Good afternoon and thanks for taking my questions. So the first one is on the HEEALING1 readout. I was just wondering if you could inform us exactly what you will disclose beyond the primary endpoint. And then on the overall IP strategy in light of what is going on now with the Phathom challenge to the FDA's interpretation of the GAIN Act. I suppose, assuming that this may take some time to fully resolve. How does this influence your development plans for H. pylori? Pylori, and how important do you see this indication being for linaprazan glurate's overall exclusivity position in the US, along with the partnering efforts? I will start there. Thanks.

Christer Ahlberg
15:04 - 20:34

Okay. First question regarding the topline results. What we are going to deliver. Of course, we will deliver the primary endpoint. And that by itself is, as I mentioned, superiority. We are measuring if we are superior versus lansoprazole in the target population of severe patients with grade C and D erosive GERD. We also intend to deliver those results in four weeks. So, actually, we will have already answered the question there of whether we are. We have better healing and we have faster healing. So these two in combination. And then of course, in the secondary endpoint, we will also look into healing of erosive esophagitis. Also in eight weeks, for the C and D patients, but also for all patients. All patients. And that will, of course, be announced. The outcome of that. And then we have also an endpoint with symptom relief, number of heartburn-free days. And that is of course something that we will also inform about. So, the primary endpoints as well as the secondary endpoints will be in one way or another communicated. So that is the first question. Second question regarding the FDA discussions and the PDR case. Now, regarding the extension of the data exclusivity for all indications if you pursue the H. pylori indication. Pylori indication, that is of course an interesting question, which the FDA actually went through with thorough investigations just recently during last year, both from a regulatory and a legal point of view, and they have changed their view on that. And actually, they have changed to our favor, so to say, so that you can include all indications; the extension is for the substance, so to say, and not only for the indication. And that is, of course, the incentive they want to give. That is the background of this kind of incentive, as they want companies to pursue development and research on infectious diseases. We appreciate their decision to do that. They get an extension of the substance exclusivity, and they have come to the conclusion as late as last year that this is definitely part of that. When we look into this, we do not believe there is any reason to think they will change their minds, as we are confident they have done their homework thoroughly from a legal point of view. So we definitely think that they will stick to what they have decided and also in a potential court case. And how long that takes. It is difficult to say. It is very difficult to say. We do not know, as we have investigated, but there is obviously a risk that it can take some time. And then of course, the question is, as you say, what about the H. pylori strategy then? Of course, we need to take a decision at a certain time whether we should go with H. pylori. For us, we believe that when it comes to the market potential of H. pylori, it is a very interesting market potential in other markets as well, including outside the US. In fact, H. pylori is a huge problem in Europe, especially in Eastern Europe, but also in many other markets. so. Therefore, we believe that H. Pylori could still be of interest to develop and find a product or a combination that actually provides very effective eradication of H. pylori. At the same time, you reduce the risk of antibiotic resistance and also reduce the side effects associated with the current standard of care. And that is the combination we think could be very attractive from a market point of view and definitely has a chance to become the new standard of care outside the US. So definitely H. pylori is absolutely an interesting indication with or without this data exclusivity extension in the US.

Unknown 1
20:38 - 20:41

Thank you. That is very clear. I will jump back in the queue.

Christer Ahlberg
20:45 - 20:46

Okay. More questions.

Operator
20:48 - 20:52

The next question comes from Georg Tegoprazan-Bjork from ABG. Please go ahead.

Unknown 1
20:55 - 21:41

Yeah. Hi, this is Georg from ABG. Thank you for taking my questions. I have two questions, please. So, firstly, on HEEALING. So, the data there in the Phase II protocol C and D subgroup for linaprazan glurate 75 mg showed a 93% healing rate versus 38% for lansoprazole. I am curious if you could comment on what you consider the absolute superiority margin that you regard as a commercial win. So in other words, what is the real bar here? And then, do you mean finally or second?

Christer Ahlberg
21:42 - 21:43

Okay. Sorry. Go ahead.

Unknown 1
21:43 - 22:11

Yeah. And then secondly, I follow up on H. pylori and the potential five-year exclusivity extension, if I may, and that is assuming positive HEEALING1 readout. Pylori and the potential five-year exclusivity extension, if I may, and that is assuming positive HEEALING1 readout. What is your base case for sequencing the H. pylori and erosive GERD trials and approvals? In other words, would the strategy there require delaying the US approval for Erosive GERD, or how do you see that? Thank you.

Christer Ahlberg
22:14 - 22:31

Okay. Let's start. Did I understand the question correctly that you are asking what margin and delta we are estimating to be best in class versus PPI? Was that the question?

Unknown 1
22:33 - 22:38

Correct. Best in class or commercial in other terms as well.

Christer Ahlberg
22:38 - 22:40

Okay. I mean.

Unknown 1
22:40 - 22:44

I appreciate it. Of course, if you cannot comment on that. But yes. Yeah.

Christer Ahlberg
22:46 - 26:47

I think I tried to explain here first. There are different views when it comes to healing. It is, of course, from a regulatory point of view and also from a physician's point of view, that healing is the key endpoint. Treating the patients. And that is also what you get registered on from a regulatory point of view. And when you look into the healing, there are always different angles from which you can consider it. We have developed a product originally to reach full acid control, which we know is needed to also help the most severe patients to be healed. And that is something that we have done from the beginning when we started this project to try to optimize the substance. So we make sure that you get more or less 100% acid control, since we know that the correlation is there. And when we look into our program, when it comes to healing, firstly, we want to deliver healing very fast. We want to deliver it in half the time compared to what is standard and approved currently, meaning that we want to deliver healing in four weeks. So, more or less complete, full, and very close to full healing already after four weeks. And that is by itself a very important differentiator. Because if you ask a patient if they want to be symptom-free in four weeks or in eight weeks, they will certainly know the answer to that. Next, of course, is that you want to heal as many patients as possible with the highest healing rate possible, close to 100%. The tricky thing with that is, of course, that the milder the patients are, the easier it is to heal them. So it is also easier to reach the 100%. We need to hold two thoughts in our heads at the same time when we look into healing, because healing in absolute figures is one metric, but you need to combine it with the delta compared to the comparator. Because if you have to heal patients, then the comparator will also have high healing rates, so therefore you need to look at it as a quality check. The delta and incremental benefit you get versus the PPI, the bigger the delta is, the better it is, of course. So what we have seen with our competitors is that they have a delta between lansoprazole and themselves in eight weeks for the severe patient population of approximately 15% to 20%. That is what I would say in combination with a good absolute figure in healing. So these are the figures we are looking into: fast healing, effective healing, and also the highest delta possible. So these three we will look into quite carefully, and I will not go into much detail regarding the specific figures we are looking for. But with that said, the second question was, can you repeat that please? Sorry.

Unknown 1
26:48 - 27:07

Of course. So, I am wondering about the sequencing of the H. pylori program versus erosive GERD in order to have H. pylori first approved for getting the potential five-year exclusivity. Pylori, first approved for getting the potential five-year exclusivity. How do you see that in the base case? Thank you.

Christer Ahlberg
27:07 - 30:21

Yes. Thank you. Before we go into that, healing is one thing when we are discussing this differentiation. But I think also when you look into the study later on, we are also looking into symptom relief, of course, because if I say that healing is what the physicians and the regulatory authorities are looking for, we would say that symptom relief is what the patients are looking for. Of course, if we can deliver superior symptom relief, that is also a very important differentiation factor in this case as well. We are looking at both healing and symptom relief when considering the timing of H. pylori in relation to the erosive GERD indication. Pylori in relation to erosive GERD indication. And when it comes to H. pylori, When it comes to H. pylori, that is an acute disease. The clinical studies are much shorter. You need to do a 14-day treatment plus a 14-day follow-up. You do not need to have a long-term maintenance treatment or anything like that. So it is a fast clinical study that needs to be performed. And we do not need to conduct any Phase II trial. We will conduct a Phase I trial where we will define the dosing. So it will be a phase one dose-finding trial. And directly based on the right dose, we will go directly into the Phase III study. As I said, since these trials are quite straightforward, they are quite fast to execute. So we are looking into the start of HEEALING2, and of course, we need to start up the H. pylori program in parallel at a certain time to make sure that if we can go in with H. pylori eradication in the US, we ensure that we get the H. pylori indication first, and we also need to remind ourselves that we have a fast track. We have an accelerated process approved by the FDA. So. We have an accelerated process with the FDA for the H. pylori indication. So, by. Even though. If we go submit the two indications at the same time, the H. Pylori will be approved faster. But, of course, we have control of that. And if we're going to do H. Pylori here now, then we need to start it in parallel at a certain time. Okay. Are there any other questions?

Unknown 1
30:23 - 30:24

Great. No, thanks. That is all for me.

Operator
30:29 - 30:46

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Christer Ahlberg
30:47 - 39:26

Well, there are some written questions also. I can bring up some comments on the Chinese launch. Linaprazan glurate is the third product that has been launched now in China. A third PCAB and the uptake looks very promising. It is Huadong and Sinorda. They are doing a great job in China, and the progress looks very promising. And we. That is a very good sign of that. The product is working and has good efficacy, and the patients actually like what they get. That is what I mean, and of course, it is also interesting to note that we are the third PCAB launched in the market with a launch looking very promising. And I think that is confirming also what we have said, that the PCAB market looks very similar to the PPI markets, where we had in total six different PPIs launched in the market where all of the six of them became blockbusters. So this is such a huge market and so many patients. There is room for more than, as we see in PPIs, a handful of different products with different strengths and differentiation and positioning in the market. So, I think this confirms that once again, as we have said. Another question that has been raised is regarding the commercialization plans in the US. Regarding our plans there, what I can say is that we are investigating. We are exploring different options. Of course, as a company, we have purposely waited to partner up the US rights. And actually, we are also looking into whether it is a possibility to commercialize this ourselves in the US, since this is a specialty pharma play where you can, with a specialty pharma sales force of up to 80 sales reps, potentially have a very effective and successful launch. So that is one path that we are investigating, and we are looking into other options. The other part is, of course, to partner up for the US. That could of course also be a very interesting path for us where we, together with a partner, develop the final step, the last clinical study, and prepare for commercialization in the US. Of course, that would be very supportive from a financial point of view to go all the way with the HEEALING2 study and finance it. And then, of course, there are hybrids between these two alternatives with co-promotion possibilities. We are preparing for all alternatives. And at this stage, we have not decided which path is the first option, so to say, going forward. Regarding generics in the US, there are discussions on whether the exclusivity for Vonoprazan will be prolonged or not. I indicated that earlier in the call. When we started to develop this product from the beginning, our aim has always been to reach 24-hour acid control, which is unique to us. And now we have a product that is definitely unique. No other PCABs are close to what we have when it comes to acid control. So in that world, we have also been aware that we will compete versus PCAB generics. So this does not change the scenario planning for us; whether Vonoprazan goes off patent in '32, '34, or whenever, we have prepared ourselves to ensure we have a best-in-class profile to meet the unmet medical needs of severe patients who are not being treated well with current therapies. So there is definitely always a place for a product delivering something superior versus the current treatment, no matter what is on generics or if it is with a premium price. So, I think this is well-prepared and it does not have any major impact on our thoughts and strategies going forward. And. Let's see what more we have. Yeah. We have also received questions regarding the outcome of the HEEALING1 study and the importance of ranking the different end points to determine which are the most significant. It is actually not that easy to say which one is the most important or not. I have tried to describe the perspectives from which we will evaluate these results. We aim for the fastest healing. That is what we want to deliver. Of course, we want to have the best healing, but we also want to have the highest delta in comparison. This could be a different combination, of course, within different patient groups. On top of that, of course, we are very curious to learn more about the symptom. Symptom freedom and actually symptom relief are key endpoints. So I think this is also an interesting endpoint that we will also investigate further and scrutinize the different data that we receive. Regarding the timing of the decision to partner up, I cannot say. Of course, this is an ongoing process that we have at all times. We have ongoing discussions with different potential partners, but we are also planning to commercialize the drug ourselves. So we are doing this in parallel. But, of course, we want to have faith in the future and keep it in our own hands. So, we need to be ready and prepared for whenever and whatever we decide to go for. Okay. I think. That was it for today. I do not see that we have any more questions here in the written part as well. I think I will stop here and thank you for listening and wish you a good afternoon. Thank you very much.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…